These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29727562)

  • 1. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.
    Grasso M; Estrada MA; Berrios KN; Winkler JD; Marmorstein R
    J Med Chem; 2018 Jun; 61(11):5034-5046. PubMed ID: 29727562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF
    Grasso M; Estrada MA; Ventocilla C; Samanta M; Maksimoska J; Villanueva J; Winkler JD; Marmorstein R
    ACS Chem Biol; 2016 Oct; 11(10):2876-2888. PubMed ID: 27571413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
    Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z
    ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
    J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of BRAF dimers using an allosteric site.
    Cotto-Rios XM; Agianian B; Gitego N; Zacharioudakis E; Giricz O; Wu Y; Zou Y; Verma A; Poulikakos PI; Gavathiotis E
    Nat Commun; 2020 Sep; 11(1):4370. PubMed ID: 32873792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
    Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
    Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Highly Sensitive Biosensors of RAF Dimerization in Cells.
    Miyamoto K; Sawa M
    Sci Rep; 2019 Jan; 9(1):636. PubMed ID: 30679688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib.
    Tkacik E; Li K; Gonzalez-Del Pino G; Ha BH; Vinals J; Park E; Beyett TS; Eck MJ
    J Biol Chem; 2023 May; 299(5):104634. PubMed ID: 36963492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors.
    Rasmussen DM; Semonis MM; Greene JT; Muretta JM; Thompson AR; Toledo Ramos S; Thomas DD; Pomerantz WCK; Freedman TS; Levinson NM
    Elife; 2024 May; 13():. PubMed ID: 38742856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.
    Tse A; Verkhivker GM
    PLoS One; 2016; 11(11):e0166583. PubMed ID: 27861609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
    Wang L; Zhu G; Zhang Q; Duan C; Zhang Y; Zhang Z; Zhou Y; Lu T; Tang W
    Org Biomol Chem; 2017 Apr; 15(16):3455-3465. PubMed ID: 28368067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.
    Verkhivker GM
    Mol Biosyst; 2016 Oct; 12(10):3146-65. PubMed ID: 27481329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of the oncogenic BRAF
    Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
    J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
    Yao Z; Torres NM; Tao A; Gao Y; Luo L; Li Q; de Stanchina E; Abdel-Wahab O; Solit DB; Poulikakos PI; Rosen N
    Cancer Cell; 2015 Sep; 28(3):370-83. PubMed ID: 26343582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Path Forward for RAF Therapies: Inhibition of Monomers and Dimers.
    Kortum RL; Morrison DK
    Cancer Cell; 2015 Sep; 28(3):279-81. PubMed ID: 26373275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives.
    Okaniwa M; Hirose M; Arita T; Yabuki M; Nakamura A; Takagi T; Kawamoto T; Uchiyama N; Sumita A; Tsutsumi S; Tottori T; Inui Y; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    J Med Chem; 2013 Aug; 56(16):6478-94. PubMed ID: 23906342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.